Expression and prognostic impact of CD49b in human lung cancer. Issue 6 (11th February 2022)

• Record Type: Journal Article
• Authors: Tirilomi, Anna; Elakad, Omar; Yao, Sha; Li, Yuchan; Hinterthaner, Marc; Danner, Bernhard C.; Ströbel, Philipp; Tirilomis, Theodor; Bohnenberger, Hanibal; von Hammerstein-Equord, Alexander
• Editors: Mojumdar., Kamalika
• Is Part Of: Medicine. Volume 101:Issue 6(2022)
• Page Start: e28814
• Publication Date: 2022-02-11
• Subjects: cluster of differentiation 49b -- human lung cancer; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000028814
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: Lung cancer remains the worldwide leading cause of cancer-related death. Currently, prognostic biomarkers for the detection and stratification of lung cancer are being investigated for clinical use. The surface protein cluster of differentiation 49b (CD49b) plays an important role in promoting cell proliferation and invasion in different tumor entities and blocking CD49b improved the tumor immune response. Overexpression of CD49b has been associated with unfavorable survival rates in several malignant tumor entities, such as prostate cancer, gastric cancer and colon cancer. Therefore, we aimed to analyze the protein expression of CD49b in patients with different types of lung cancer and additionally to identify the influence of CD49b on clinicopathological characteristics and overall survival. Expression levels of CD49b were retrospective analyzed by immunohistochemistry in 92 cases of pulmonary adenocarcinoma (AC), 85 cases of squamous cell lung carcinoma (SQCLC) and 32 cases of small cell lung cancer (SCLC) and correlated with clinicopathological characteristics and patients' overall survival. A strong expression of CD49b was most seen in SQCLC (78%), followed by AC (48%) and SCLC (9%). All patients combined, strong expression of CD49b correlated significantly with poorer overall survival. However, an increased expression of CD49b correlated significantly with a poorer survival rate only in SQCLC. In AC and SCLC, no significant correlation could be demonstrated in this regard. In our study, CD49b expression was associated with poor overall survival in patients with SQCLC. Accordingly, CD49b could serve as a new prognostic biomarker and, moreover, be a potential new drug target in SQCLC.